News | May 12, 2025
Dabur India posts Q4 FY25 consolidated PAT at Rs. 320.13 Cr
The company has posted net profit of Rs. 1,767.63 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 1,767.63 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 55.36 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs.168.16 crores for the Financial Year ended March 31, 2025
This marks yet another milestone in our series of successful audits over the past year
ISPP will analyze health systems across states, identifying scalable models and actionable insights to strengthen India's healthcare delivery
Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
The change of name has been carried on pursuant to the Scheme of Amalgamation
Subscribe To Our Newsletter & Stay Updated
